# US 10,370,378 B2 · Treatment of sleep disorders > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 10,370,378 B2 - Document ID: US10370378B2 - Status: Granted - Kind: B2 - Application number: 14/244,085 - Filed: 2014-04-03 - Published: 2014-08-14 - Granted: 2019-08-06 - Earliest claimed: 2007-08-20 - Assignees: Evotec International GmbH - Applicants: Evotec International GmbH - Inventors: John Alan Kemp; Ian Michael Hunneyball; Timothy Tasker - Web page: https://patentgrep.com/patent/US10370378B2 ## CPC - C07D 487/04: Ortho-condensed systems - A61K 31/5517: condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam - A61P 25/20: Hypnotics; Sedatives - A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 - C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08) - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS ## Abstract The use of 7-chloro-3-(5-dimethylaminomethyl-[1,2,4]oxadiazol-3-yl)-5methyl-4,5-dihydro-imidazol[1,5,-a][1,4]benzodiazepine-6-one or its pharmaceutically acceptable salt for treating various types of insomnia. ## Claims ### Claim 1 A method for treating maintenance insomnia in a human in need thereof comprising administering to the human before bedtime an amount of a compound of formula (II) or a pharmaceutically acceptable salt thereof effective to treat the maintenance insomnia and to increase total sleep time in a period of about four to about eight hours after administration ### Claim 2 (depends on 1) The method according to claim 1, wherein the amount of the compound of formula (II) or the pharmaceutically acceptable salt thereof is from about 0.5 mg to about 5 mg. ### Claim 3 (depends on 1) The method according to claim 1, wherein the amount of the compound of formula (II) or the pharmaceutically acceptable salt thereof is from about 1 mg to about 3 mg. ### Claim 4 (depends on 1) The method according to claim 1, wherein the amount of the compound of formula (II) or the pharmaceutically acceptable salt thereof is from about 1.5 mg to about 2.5 mg. ### Claim 5 (depends on 1) The method according to claim 1, wherein the human is at least 65 years old. ### Claim 6 A method for treating terminal insomnia in a human in need thereof comprising administering to the human before bedtime an amount of a compound of formula (II) or a pharmaceutically acceptable salt thereof effective to treat the terminal insomnia and to increase total sleep time in a period of about four to about eight hours after administration ### Claim 7 (depends on 6) The method according to claim 6, wherein the amount of the compound of formula (II) or the pharmaceutically acceptable salt thereof is from about 0.5 mg to about 5 mg. ### Claim 8 (depends on 6) The method according to claim 6, wherein the amount of the compound of formula (II) or the pharmaceutically acceptable salt thereof is from about 1 mg to about 3 mg. ### Claim 9 (depends on 6) The method according to claim 6, wherein the amount of the compound of formula (II) or the pharmaceutically acceptable salt thereof is from about 1.5 mg to about 2.5 mg. ### Claim 10 (depends on 6) The method according to claim 6, wherein the human is at least 65 years old. ### Claim 11 (depends on 6) The method according to claim 6, which is also for treatment of maintenance insomnia, wherein the compound of formula (II) or the pharmaceutically acceptable salt thereof is administered to the human in need of treatment of the maintenance insomnia and the terminal insomnia. ### Claim 12 A method for increasing total sleep time in a period in a human in need thereof comprising administering to the human before bedtime an amount of a compound of formula (II) or a pharmaceutically acceptable salt thereof effective to increase total sleep time in the period, which is about four to about eight hours after administration ### Claim 13 (depends on 12) The method according to claim 12, wherein the amount of the compound of formula (II) or the pharmaceutically acceptable salt thereof is from about 0.5 mg to about 5 mg. ### Claim 14 (depends on 12) The method according to claim 12, wherein the amount of the compound of formula (II) or the pharmaceutically acceptable salt thereof is from about 1 mg to about 3 mg. ### Claim 15 (depends on 12) The method according to claim 12, wherein the amount of the compound of formula (II) or the pharmaceutically acceptable salt thereof is from about 1.5 mg to about 2.5 mg. ### Claim 16 (depends on 12) The method according to claim 12, wherein the human is at least 65 years old. ### Claim 17 (depends on 12) The method according to claim 12, wherein the period is from about five to about eight hours after administration. ### Claim 18 (depends on 12) The method according to claim 12, wherein the period is from about six to about eight hours after administration.